Though some aspects of the ITA.LI.CA system are rooted in the BCLC, it is distinct in several important ways: first, in subclassifying BCLC stage B patients into B1, B2, and B3 categories based on degree of intrahepatic tumor burden; second, in differentiating patients with intrahepatic and extrahepatic metastases; and finally, by incorporating the serum biomarker AFP. This evidence concerns the gene AFP and neoplasm.